Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.86 |
| ▸ | MAPT | P10636 | 3/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | BLM | P54132 | 2/20 | 0.86 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 2/20 | 0.86 |
| ▸ | MPO | P05164 | 1/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | APAF1 | O14727 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan SCHEMBL9486225 | 1.00 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL8406412 | 1.00 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27152251 | 1.00 | KDM4E (0.86) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL27984227 | 0.99 | KDM4E (0.84) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL28650342 | 0.99 | KDM4E (0.84) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL4756160 | 0.95 | KMT2A (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL4756156 | 0.95 | KMT2A (0.78) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL28523647 | 0.94 | KMT2A (0.76) | KDM4EMAPTKMT2ALMNATSHR | |
| Tryptophan SCHEMBL23141133 | 0.93 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR | |
| Dl-Tryptophan SCHEMBL19161120 | 0.93 | KMT2A (1.00) | KDM4EMAPTKMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117599013-A | Nanometer composition, preparation method and application thereof | 赣州和美药业股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| EP-1292609-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | HERCULES INCORPORATED | 2002-05-02 | — | — | US | claimed |
| WO-2001098364-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2001-12-27 | — | — | WO | claimed |
| US-12012593-B2 | Modified peptide display | Miti Biosystems GmbH (AT) | 2024-06-18 | — | — | US | disclosed |
| CN-117599013-A | Nanometer composition, preparation method and application thereof | 赣州和美药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11332734-B2 | Modified peptide display | Miti Biosystems GmbH (AT) | 2022-05-17 | — | — | US | disclosed |
| US-20190211323-A1 | MODIFIED PEPTIDE DISPLAY | Miti Biosystems GmbH (AT) | 2019-07-11 | — | — | US | disclosed |
| EP-3324994-A1 | METHODS OF REDUCING THE NEED FOR SURGERY IN PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA | Nymox Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170240883-A1 | CYCLIC PEPTIDES EXPRESSED BY A GENETIC PACKAGE | Miti Biosystems GmbH (AT) | 2017-08-24 | — | — | US | disclosed |
| EP-3180431-A1 | CYCLIC PEPTIDES EXPRESSED BY A GENETIC PACKAGE | Miti Biosystems GmbH (AT) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017019593-A1 | METHODS OF REDUCING THE NEED FOR SURGERY IN PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA | NYMOX CORPORATION (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2603586-A1 | MODIFIED PEPTIDE DISPLAY | Christiansen, Guntram (AT) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012019928-A1 | MODIFIED PEPTIDE DISPLAY | CHRISTIANSEN GUNTRAM (AT) | 2012-02-16 | — | — | WO | disclosed |
| US-20110294983-A1 | SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS | COMPLIX NV (BE) | 2011-12-01 | — | — | US | disclosed |
| EP-1292609-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | HERCULES INCORPORATED | 2002-05-02 | — | — | US | disclosed |
| WO-2001098364-A2 | PEPTIDES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BURKHOLDERIA CEPACIA | HERCULES INCORPORATED (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-0927259-A1 | MODIFIED alpha-AMYLASES HAVING ALTERED CALCIUM BINDING PROPERTIES | GENENCOR INTERNATIONAL, INC. (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1997043424-A1 | MODIFIED α-AMYLASES HAVING ALTERED CALCIUM BINDING PROPERTIES | GENENCOR INTERNATIONAL, INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051819-A1 | Peptides, compositions and methods for the treatment of burkholderia cepacia | NGLY1, VIP, CSTB | KDM4E 4776/4885MAPT 4266/4885KMT2A 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.